Axogen, Inc. (LON:0HKD)
30.01
+0.08 (0.26%)
At close: Dec 12, 2025
Axogen Revenue
Axogen had revenue of $60.08M USD in the quarter ending September 30, 2025, with 23.51% growth. This brings the company's revenue in the last twelve months to $214.71M, up 18.72% year-over-year. In the year 2024, Axogen had annual revenue of $187.34M with 17.81% growth.
Revenue (ttm)
$214.71M
Revenue Growth
+18.72%
P/S Ratio
6.57
Revenue / Employee
$475.02K
Employees
452
Market Cap
1.05B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 187.34M | 28.33M | 17.81% |
| Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
| Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
| Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
| Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
| Dec 31, 2019 | 106.71M | 22.78M | 27.13% |
| Dec 31, 2018 | 83.94M | 23.51M | 38.91% |
| Dec 31, 2017 | 60.43M | 19.32M | 46.99% |
| Dec 31, 2016 | 41.11M | 13.78M | 50.41% |
| Dec 31, 2015 | 27.33M | 10.51M | 62.52% |
| Dec 31, 2014 | 16.82M | 5.87M | 53.62% |
| Dec 31, 2013 | 10.95M | 3.26M | 42.33% |
| Dec 31, 2012 | 7.69M | 2.84M | 58.61% |
| Dec 31, 2011 | 4.85M | 1.85M | 61.41% |
| Dec 31, 2010 | 3.00M | -21.91M | -87.94% |
| Dec 31, 2009 | 24.91M | 24.84M | 34,160.81% |
| Dec 31, 2008 | 72.71K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Axogen News
- 12 hours ago - Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN) - GuruFocus
- 2 days ago - Insider Sell: Paul Thomas Sells 21,399 Shares of Axogen Inc (AXGN) - GuruFocus
- 7 days ago - AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Buy Rating | AXGN Stock News - GuruFocus
- 8 days ago - Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Buy Rating | AXGN Stock News - GuruFocus
- 8 days ago - Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment - Benzinga
- 8 days ago - FDA Approves Axogen's (AXGN) Avance for Nerve Repair - GuruFocus
- 9 days ago - Axogen gets FDA OK for Avance’s biologics license application - Seeking Alpha
- 9 days ago - FDA Approves Axogen's AVANCE Nerve Allograft For Peripheral Nerve Repair - Nasdaq